Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Antigenics will acquire Aronex Pharmaceuticals, gaining a product pipeline containing six late-stage drugs including Atragen for acute promyelocytic leukemia.
FDA declined to approve Atragen, stating Aronex's data did not establish an identifiable population of APL patients who need tretinoin and cannot use the oral…
Antigenics' 10-K disclosed acquired Aronex assets including Atragen, Annamycin, and Nyotran; subsequent filings reflect impairment and discontinuation of…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Antigenics acquired Aronex Pharmaceuticals for approximately $28.6 million, adding liposomal oncology assets (Atragen for acute promyelocytic leukemia, Annamycin, and Nyotran) to its heat-shock-protein-based cancer-vaccine platform. The Aronex programs were subsequently impaired or discontinued as Antigenics refocused on its lead candidate Oncophage.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Antigenics Inc. / Aronex Pharmaceuticals Inc. (this deal) | 2001 | $29M | — |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals